Trial Profile
An Open Label Pilot Study of Denosumab Treatment for Fibrous Dysplasia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone disorders; Fibrous dysplasia of bone
- Focus Biomarker; Pharmacodynamics
- 17 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2019 Planned primary completion date changed from 15 Mar 2030 to 11 Mar 2026.
- 15 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 4 Jun 2019 to 13 Jun 2019.